Earnings Call · Q2 FY2023·2023-08-08

Q2 23EPS +6.90%·Rev n/aQ1 23EPS +69.35%·Rev n/aQ4 22EPS +32.56%·Rev n/aQ3 22EPS +1.15%·Rev n/a⚠ consensus missing

FATE THERAPEUTICS INC FATE

Scott Wolchko — President and CEO

Ed Dulac — Chief Financial Officer

−3.7%1d on move date−3.0% vs SPY3d−12.5%5d−17.0%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more FATE calls or request research access.

More FATE calls Browse calls Request research access